ARDELYX, INC. Q3 FY2025 earnings call

Management Statement and Operational Highlights \n- Mike Raab: Outlined key priorities for the year, including accelerating IBSRELA's momentum, executing on XPHOZAH strategy, building the pipeline, and delivering strong financial performance. IBSRELA had record Q3 revenue with 92% YOY growth, and XPHOZAH had strong Q3 revenue. Announced ARDX-10531 (531) as the next-gen NHE3 inhibitor, marking pipeline reinvigoration. \n- Eric Foster: Highlighted IBSRELA's strong Q3 performance with record revenue, growth in new and total writers, and improved prescription pull-through. Focused on patient engagement, prescriber engagement, and continued investment in patient marketing. XPHOZAH's growth, focus on access, clinical conviction, and stakeholder engagement. \n- Justin Renz: Discussed financials, with total revenue at $110.3 million, 12% YOY growth. Raised IBSRELA guidance to $270-275 million for the year. XPHOZAH revenue at $27.4 million, strong balance sheet with $242.7 million in cash, cash equivalents, and short-term investments.

Segment Performance \n- IBSRELA: Generated $78.2 million in the third quarter, a 92% increase year-over-year. This represents approximately 74.1% of the total product revenue of $105.5 million. The IBSRELA team is focusing on expanding reach and deepening prescriber engagement. \n- XPHOZAH: Generated $27.4 million in revenue during the third quarter, a 9% increase compared to Q2. This accounts for approximately 25.9% of the total product revenue. The XPHOZAH team is working on ensuring patient access, strengthening clinical conviction among nephrologists, and driving prescription pull-through.

Guidance \n- Raised IBSRELA revenue guidance to between $270 million and $275 million for the year. \n- XPHOZAH is expected to contribute more to the business over time. \n- Announcement of ARDX-10531, a next-generation NHE3 inhibitor, marking the start of pipeline reinvigoration.

Risks \n- Forward-looking statements are subject to risks and uncertainties, and actual results may differ significantly from those described. The company disclaims any obligation to update forward-looking statements even if views change. Refer to the most recent quarterly report on Form 10-Q for detailed risk factors.

Question and Answer \nQ: On IBSRELA frontline share and 10531 indications\nA: Mike Raab and Eric Foster discussed IBSRELA's organic growth and 10531's preclinical stage, noting IBSRELA's potential in second-line therapy and 10531's early development phase\nQ: On XPHOZAH acceleration\nA: Mike Raab and Eric Foster discussed XPHOZAH's market access efforts, clinical conviction among nephrologists, and team efforts to drive growth\nQ: On the new 531 program\nA: Michael Raab explained that 531 is in early preclinical stages, with focus on exploring its potential in various therapeutic areas based on its unique properties\nQ: On business development activities\nA: Michael Raab stated the company will be opportunistic in exploring therapeutic areas adjacent to current ones, with a focus on strategic and complementary opportunities